| Clinically isolated syndrome
Tascenso ODT vs Vumerity
Side-by-side clinical, coverage, and cost comparison for clinically isolated syndrome.Deep comparison between: Tascenso Odt vs Vumerity with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsVumerity has a higher rate of injection site reactions vs Tascenso Odt based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Vumerity but not Tascenso Odt, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Tascenso Odt
Vumerity
At A Glance
Oral
Daily
Sphingosine 1-phosphate receptor modulator
Oral
Twice daily
Nrf2 pathway activator
Indications
- Clinically isolated syndrome
- Multiple Sclerosis, Relapsing-Remitting
- Multiple Sclerosis, Secondary Progressive
- Clinically isolated syndrome
- Multiple Sclerosis, Relapsing-Remitting
- Multiple Sclerosis, Secondary Progressive
Dosing
Clinically isolated syndrome, Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Secondary Progressive Adults and pediatric patients (10 years and older) weighing more than 40 kg: 0.5 mg orally once daily, with or without food; pediatric patients (10 years and older) weighing 40 kg or less: 0.25 mg orally once daily, with or without food.
Clinically isolated syndrome, Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Secondary Progressive Starting dose 231 mg twice daily orally for 7 days; maintenance dose 462 mg (two 231 mg capsules) twice daily orally; temporary reduction to 231 mg twice daily may be considered for tolerability, resuming 462 mg twice daily within 4 weeks.
Contraindications
- Myocardial infarction, unstable angina, stroke, TIA, decompensated heart failure requiring hospitalization, or Class III/IV heart failure within the last 6 months
- History or presence of Mobitz Type II second-degree or third-degree AV block or sick sinus syndrome without a functioning pacemaker
- Baseline QTc interval >= 500 msec
- Cardiac arrhythmias requiring anti-arrhythmic treatment with Class Ia or Class III anti-arrhythmic drugs
- Previous hypersensitivity reaction to fingolimod or any excipient (including rash, urticaria, or angioedema)
- Concomitant use with other products containing fingolimod
- Known hypersensitivity to diroximel fumarate, dimethyl fumarate, or any excipient of VUMERITY (reactions may include anaphylaxis and angioedema)
- Concomitant use of dimethyl fumarate
Adverse Reactions
Most common (>=10%) Headache, liver transaminase elevation, diarrhea, cough, influenza, sinusitis, back pain, abdominal pain, pain in extremity
Serious Bradyarrhythmia, AV blocks, infections, progressive multifocal leukoencephalopathy, macular edema, liver injury, posterior reversible encephalopathy syndrome, fetal risk, malignancies, hypersensitivity reactions
Postmarketing Hemolytic anemia, thrombocytopenia, liver injury, cryptococcal infections, HPV infection, PML, arthralgia, myalgia, PRES, seizures, melanoma, Merkel cell carcinoma, cutaneous T-cell lymphoma, Kaposi's sarcoma, squamous cell carcinoma, hypersensitivity
Most common (>=10%) Flushing, abdominal pain, diarrhea, nausea
Serious Anaphylaxis, angioedema, progressive multifocal leukoencephalopathy, herpes zoster and other serious opportunistic infections, lymphopenia, liver injury, serious gastrointestinal reactions
Postmarketing Acute pancreatitis, gastrointestinal perforation/ulceration/obstruction/hemorrhage, liver function abnormalities (transaminases >=3 times ULN with total bilirubin >2 times ULN), herpes zoster infection, rhinorrhea, alopecia
Pharmacology
Fingolimod is metabolized to fingolimod-phosphate, a sphingosine 1-phosphate (S1P) receptor modulator that binds with high affinity to S1P receptors 1, 3, 4, and 5, blocking lymphocyte egress from lymph nodes and reducing peripheral blood lymphocyte counts, thereby limiting lymphocyte migration into the central nervous system.
Diroximel fumarate is a prodrug converted to its active metabolite monomethyl fumarate (MMF), which activates the Nrf2 pathway involved in cellular response to oxidative stress and acts as a nicotinic acid receptor agonist in vitro; the mechanism by which it exerts therapeutic effect in multiple sclerosis is unknown.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Tascenso Odt
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (0/12) · Qty limit (9/12)
Vumerity
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (5/12) · Qty limit (10/12)
UnitedHealthcare
Tascenso Odt
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (1/8)
Vumerity
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Tascenso Odt
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (2/3) · Qty limit (3/3)
Vumerity
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAccessia Health: Multiple Sclerosis - Private Insurance: Waitlist
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableAccessia Health: Multiple Sclerosis - Private Insurance: Waitlist
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
Tascenso OdtView full Tascenso Odt profile
VumerityView full Vumerity profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.